EP4480485A3 - Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions - Google Patents

Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions Download PDF

Info

Publication number
EP4480485A3
EP4480485A3 EP24191377.1A EP24191377A EP4480485A3 EP 4480485 A3 EP4480485 A3 EP 4480485A3 EP 24191377 A EP24191377 A EP 24191377A EP 4480485 A3 EP4480485 A3 EP 4480485A3
Authority
EP
European Patent Office
Prior art keywords
compounds
treatment
protein kinase
ripk3
ripk2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24191377.1A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4480485A2 (en
Inventor
Gregory Cuny
Alexei Degterev
Sameer NIKHAR
Siddharth Balachandran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Cancer Research
Tufts University
University of Houston System
Original Assignee
Institute for Cancer Research
Tufts University
University of Houston System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Cancer Research, Tufts University, University of Houston System filed Critical Institute for Cancer Research
Publication of EP4480485A2 publication Critical patent/EP4480485A2/en
Publication of EP4480485A3 publication Critical patent/EP4480485A3/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP24191377.1A 2019-05-16 2020-05-14 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions Pending EP4480485A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962848719P 2019-05-16 2019-05-16
US201962848648P 2019-05-16 2019-05-16
PCT/US2020/032784 WO2020232190A1 (en) 2019-05-16 2020-05-14 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
EP20729566.8A EP3968991B1 (en) 2019-05-16 2020-05-14 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP20729566.8A Division EP3968991B1 (en) 2019-05-16 2020-05-14 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions

Publications (2)

Publication Number Publication Date
EP4480485A2 EP4480485A2 (en) 2024-12-25
EP4480485A3 true EP4480485A3 (en) 2025-02-26

Family

ID=70919255

Family Applications (2)

Application Number Title Priority Date Filing Date
EP24191377.1A Pending EP4480485A3 (en) 2019-05-16 2020-05-14 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
EP20729566.8A Active EP3968991B1 (en) 2019-05-16 2020-05-14 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20729566.8A Active EP3968991B1 (en) 2019-05-16 2020-05-14 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions

Country Status (6)

Country Link
US (1) US20220194937A1 (enExample)
EP (2) EP4480485A3 (enExample)
JP (2) JP7546603B2 (enExample)
AU (1) AU2020275304B2 (enExample)
CA (1) CA3137869A1 (enExample)
WO (1) WO2020232190A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11174255B2 (en) * 2017-05-15 2021-11-16 University Of Houston System Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases
US20220194937A1 (en) * 2019-05-16 2022-06-23 University Of Houston System Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
CN113072471B (zh) * 2021-03-02 2022-09-16 四川美大康华康药业有限公司 一种利非司特中间体及其制备方法
WO2024097805A1 (en) * 2022-11-01 2024-05-10 Trustees Of Tufts College Mixed lineage kinase domain like pseudokinase (mlkl) activators
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034867A1 (en) * 1995-05-03 1996-11-07 Warner-Lambert Company PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION
WO1999009030A1 (en) * 1997-08-20 1999-02-25 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
WO2001055148A1 (en) * 2000-01-27 2001-08-02 Warner-Lambert Company Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
WO2014031571A1 (en) * 2012-08-21 2014-02-27 Icahn School Of Medicine At Mount Sinai Treatment of viral infections
WO2015179436A1 (en) * 2014-05-19 2015-11-26 Sanford-Burnham Medical Research Institute Inflammation therapy using mekk3 inhibitors or blocking peptides
WO2018213219A1 (en) * 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220194937A1 (en) * 2019-05-16 2022-06-23 University Of Houston System Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996034867A1 (en) * 1995-05-03 1996-11-07 Warner-Lambert Company PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION
WO1999009030A1 (en) * 1997-08-20 1999-02-25 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
WO2001055148A1 (en) * 2000-01-27 2001-08-02 Warner-Lambert Company Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
WO2014031571A1 (en) * 2012-08-21 2014-02-27 Icahn School Of Medicine At Mount Sinai Treatment of viral infections
WO2015179436A1 (en) * 2014-05-19 2015-11-26 Sanford-Burnham Medical Research Institute Inflammation therapy using mekk3 inhibitors or blocking peptides
WO2018213219A1 (en) * 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases

Also Published As

Publication number Publication date
AU2020275304A1 (en) 2021-12-16
JP2024170457A (ja) 2024-12-10
WO2020232190A1 (en) 2020-11-19
EP3968991C0 (en) 2024-07-31
US20220194937A1 (en) 2022-06-23
CA3137869A1 (en) 2020-11-19
JP2022533182A (ja) 2022-07-21
EP3968991A1 (en) 2022-03-23
JP7546603B2 (ja) 2024-09-06
AU2020275304B2 (en) 2025-01-23
EP3968991B1 (en) 2024-07-31
EP4480485A2 (en) 2024-12-25

Similar Documents

Publication Publication Date Title
EP4480485A3 (en) Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
ZA202101960B (en) Protein tyrosine phosphatase inhibitors
ZA201800022B (en) Substituted heterocyclyl derivatives as cdk inhibitors
EA033689B9 (ru) Ингибиторы g12c kras
WO2016164675A8 (en) Substituted quinazoline compounds and methods of use thereof
ZA202204284B (en) Inhibitors of raf kinases
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
WO2019177375A8 (ko) 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
PH12016502103B1 (en) Novel disubstituted 1,2, 4-triazine compound
HK1206726A1 (en) Imidazotriazinone compounds
MX2022015410A (es) Inhibidores de las cinasas receptoras del factor de crecimiento de fibroblastos.
EP4252755A3 (en) Therapeutic compounds
EP4065565A4 (en) RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS FOR THE TREATMENT OF DISEASE
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
WO2009038385A3 (en) Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
MX2025003515A (es) Moduladores de akt1
EA202091082A1 (ru) Композиция и способ лечения периферической т-клеточной лимфомы и кожной т-клеточной лимфомы
CL2024001756A1 (es) Inhibidores de cinasa met
EP4039267A4 (en) COMPOSITION WITH TMEM176B OR AN EXPRESSION OR ACTIVITY REGULATOR THEREOF AS AN ACTIVE INGREDIENT, FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASE
WO2020068950A8 (en) Hdac1,2 inhibitors
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3968991

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031541000

Ipc: A61K0031519000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/541 20060101ALI20250121BHEP

Ipc: A61P 31/16 20060101ALI20250121BHEP

Ipc: A61P 29/00 20060101ALI20250121BHEP

Ipc: A61P 25/28 20060101ALI20250121BHEP

Ipc: A61K 31/4375 20060101ALI20250121BHEP

Ipc: A61K 31/496 20060101ALI20250121BHEP

Ipc: A61K 31/519 20060101AFI20250121BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250826